CAPITAL MARKETS & INVESTMENT

11:00 The Venture Investor Outlook And Investing In The Science Of Tomorrow

Innovation among biotechs continues to come down the pipeline, and with investors looking to deploy their capital to the most promising areas how are some of the country’s leading investors viewing the outlook of biotech investments?

• How is the investment community viewing the current state of the private and public markets?
• How do investors spot the latest innovations?
• What are some alternative financing models? Royalty financing?
• Advice for biotech leadership and what they can learn from past events

Moderator: Katie McCarthy, Chief Development Officer, Halloran Consulting (partner)
Sean Zhang, Principal, Vivo Capital
Stephanie Sirota, CBO, RTW Investments
Jernej Godec, Principal, Atlas Venture Partner

11:50 Attracting Investors And First Steps–Advice For Early Stage Biotechs

What do you do if you need to find funding for your company, but you don’t know where to begin. This panel of experts will provide some key takeaways on what you should consider when pursuing investor capital.

• Prioritising research and development vs business issues
• How do investors think when being approached by a new company?
• How to know whether to accept or pass on an investment opportunity?

Moderator: Mike Glynn, Partner, Fox Rothschild
Laurence Blumberg, Biotech Executive, Multiple Biotechs
Tim Luker, Vice President, Venture Science, Eli Lilly
Deborah Palestrant, Partner, 5AM Ventures
Christine Brennan, Managing Director, Vertex Ventures
Regina Salvat, Principal, Sofinnova Investment

PARTNERSHIPS & DEAL MAKING

11:00 Pharma Partnering 101: Tips For Working With Big Pharma

Partnerships between biotech and pharma companies can often be the much-needed lifeblood to bring a particular therapy or drug to market. With an increasing number of biotechs continuing to spin out from academic institutions and emerge from a group of savvy entrepreneurs, exactly when to partner isn’t always so clear. This session will delve into deal making fundamentals necessary for a successful partnership.

• When to initiate discussions?
• What information is critical to share?
• Types, benefits, and drawbacks of early deals

11:50 The Increasing Role Of Emerging Deal-Making In Pharma & Biotech: New Players And New Strategies

As more new and emerging deal makers at small pharma and biotech companies rise, a trend towards commercializing products for orphan populations and specialized treatments has emerged in recent years. How are leaders in business development and M&A at growing and emerging pharmaceutical companies viewing the industry landscape? A panel of top emerging deal makers will discuss their focus, strategies, and vision for becoming leading players in the industry.

• How do emerging deal-makers think about innovation?·How to differentiate yourself in the industry
• New focus areas for 2023? What factors affect the decision-making process?
• Are deal-making strategies evolving?

13.45 A Biotech’s Toolkit To Weathering The Public Markets

Public market downturns offer a chance to reflect on what has changed and what anindustry as a whole can do differently in the future. As the sector continues to steadily recover from previous years, this session will look at new approaches to financing, operations, and partnerships which together forms a technical toolkit to ensure a biotechs survival.

• How are some of the country’s leading investors viewing the public markets at the moment?
• How can certain business operations be streamlined to ensure capital is deployed efficiently during tough times?
• Biotech on biotech? Can a well-funded biotech with a struggling pipeline workwith a cash-tight biotech with a stronger pipeline or Complementary platforms?
• How can the industry respond to the current public markets?

14:35 The Spectrum Of Strategic Venturing: Through The Lens Of CVCs

For corporate venture capital (CVC) firms, financial returns on investments are usually only part of the equation. Large corporations can use investments as a vehicle to get early access to new innovations. This session will explore the spectrum of strategic venturing where the panel investors from CVCs with different approaches share insights focusing on the biotech ecosystem.

• How do CVCs maximize the value for their company with a balance between capital and strategic objectives?
• How do CVCs measure their success? Invest early or late?
• What’s in it for the biotechs?

13:45 Future Of Oncology Pharmaceutical Partnerships: A Global Outlook For 2023 And Beyond

The oncology pharmaceutical industry is rapidly evolving, and the future looks promising for new treatments and therapies. One of the key drivers of this growth is the increasing number of partnerships and collaborations between pharmaceutical companies. These partnerships are playing a crucial role in the development of new and effective treatments for cancer. This panel will take a closer look at trends in oncology dealmaking over the past year and identify remaining areas of unmet medical need. The state of market-available oncology drugs

• Current roadblocks, activities, and opportunities in oncology partnering in 2023
• Significant trends in oncology deal-making over the past year and identifying remaining areas of unmet medical need

14:35 Emerging Activity In Orphan And Rare Diseases: Enabling Innovative Treatments Through

Partnering and Investment in rare diseases continues to attract pharma and investor attention with a new FDA-approved therapy in Q4 of 2022. With the global orphan diseases market projected to reach in excess of $500 billion by 2030, where will this future growth come from?

• How can in-licensing agreements create new opportunities for biotech and pharma?
• Getting the timing right when an opportunity arises to pursue M&A and spin offs
• What’s the future outlook and how are regulatory incentives stimulating growing investment from pharma and venture capitalists?

CAPITAL MARKETS & INVESTMENT

11:00 Building A Biotech Company - Key Milestones, Expert Tips And Strategies For Success

Building a biotech company from the ground up can be a challenging and daunting task, but with the right plan, resources, and expert advice, it can also be a rewarding and profitable venture. How to know exactly what to do and when will set any company leader up for guaranteed success. This educational session will dive into the key milestones every biotech leader needs to be thinking about, from hiring your first exec to closing your series C.

• Developing a solid business plan
• How to navigate first steps in securing funding and beyond?
• Building a strong team
• Network and collaborate and an eye on the competition

Moderator: Jeffrey Quillen, Partner, Foley Hoag
Johnna Simões, Vice President, Corporate Development, Cerevance
Ruta Laukien, Managing Partner, Graybella Capital
Jasper Bos, General Partner, Forbion

11:55 How To Prepare For A Successful Biotech IPO Or Reverse Merger

Any biotech company that has reached a certain size and is in need of investment will have to consider the critical question: is it time to go public? This discussion will focus all areas a biotech needs to be thinking about when considering an IPO.

• Why, when, and where?
• Closing a successful IPO/reverse merger
• Life after the IPO

Moderator: Bill Hicks, Co-Chair Securities and Capital Markets Practice Group, Mintz

CAPITAL DEPLOYMENT & COMMERCIALISATION

11:00 Creating A Patient-Centric Commercial Launch For Advanced Therapies

Bringing advanced therapeutics to market is no easy feat. The many technicalities involved in running trials, scaling manufacturing capabilities, market access and launch drives up end-to-end costs, meaning patients are often faced with a complex, long and expensive road to treatment. With the aim to bring CGT’s to as many patients as possible, panellists discuss commercial barriers facing CGT companies today and tried-and-tested solutions.

• What it takes to successfully take a cell or gene therapy from trials to commercialization
• How to mitigate human error and de-risk the process of commercializing advanced therapies by automating processes while also driving down costs
• How to digitize the commercial process to ensure timely patient access and increasepositive patient outcomes

Michele Korfin, COO & CCO, Gamida Cell
Adriana Herrera, VP, Head US Commercial, Kite Pharma
Robert Sexton, VP, Program & Alliance Leadership, Mustang Bio

11:55 Innovating For The Future Of Biotech: Planning For Early Commercial Success

Innovating for the future of biotech is a crucial aspect of the industry's growth and success. It is essential for biotech companies to continuously develop new products and services to stay competitive and meet the changing needs of customers. However, innovation alone is not enough, planning for early commercial success is also important to ensure that the innovations are profitable and sustainable.

• Identifying and evaluating potential commercial opportunities-Developing and implementing a commercialization strategy
• Navigating regulatory and legal considerations
• Building and nurturing partnerships
• Managing financial and funding challenge

Moderator: Joseph Goldberg, Partner, RSM